Mercaptamine ophthalmic - Orphan Europe

Drug Profile

Mercaptamine ophthalmic - Orphan Europe

Alternative Names: Cystadrops; Cysteamine chlorhydrate - Orphan Europe; Cysteamine hydrochloride - Orphan Europe; Mercaptamine hydrochloride - Orphan Europe

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orphan Europe
  • Class Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinosis
  • New Molecular Entity No

Highest Development Phases

  • Registered Cystinosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cystinosis in Middle East (Ophthalmic, Drops)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cystinosis in North Africa (Ophthalmic, Drops)
  • 27 Jan 2017 Registered for Cystinosis (In adolescents, In children, In adults) in European Union, Norway, Iceland and Liechtenstein (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top